3-Methyladenine (3-MA)

目录号:S2767 别名: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA)是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。

规格 价格 库存 购买数量  
RMB 579.66 现货
RMB 3010.37 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

  • PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

    A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 3-Methyladenine (3-MA)是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。
靶点
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
体外研究

3-MA对Vps34轻微的偏向性可能是由于Vps34中某个特异性的疏水环形结构可以环绕在3-MA的3-甲基基团外面造成的[1] 。据报道对于正常培养和饥饿处理的癌细胞3-MA都能引起细胞死亡。3-MA还可以不通过抑制自吞噬来抑制细胞迁移和入侵,这表明3-MA 除了抑制自吞噬之外还有其它生物功能。3-MA可以造成半胱天冬酶依赖的细胞死亡,这一功能与它对自吞噬的抑制无关。用5mM 3-MA处理葡萄糖饥饿Hela细胞可降低gfp-lc3阳性细胞比例至23%。3-MA处理细胞12到48小时内 LC3-I 的水平上升而LC3-II 水平下降。LC3-I转为为 LC3-II 的过程被3-MA抑制了。 2.5 mM 或5 mM 3-MA 处理HeLa 细胞一天并不影响细胞存活率, 而 10 mM 3-MA 处理一天会造成细胞存活率下降25.0% 。 2.5, 5 或 10 mM 3-MA 处理细胞两天分别使细胞存活率下降 11.5%, 38.0% 和79.4% 。3-MA 降低细胞存活率的作用具有时间和剂量依赖特性。3-MA 明显缩短nocodazole诱导的前中期阻断时间[2]。3-MA 通过抑制自吞噬来抑制SU11274诱导的细胞死亡[3]。 在野生型MEF细胞中延长 3-MA处理时间 (最多 9 小时) 明显造成 LC3 I 到 II 转换。延长 3-MA处理时间会明显增加GFP-LC3的聚集而wortmannin不具有此功能。3-MA介导的LC3 转换和游离 GFP 释放是ATG7依赖的。 3-MA处理会导致 p62 蛋白水平明显升高。即使在Atg5−/− 的MEF细胞中3-MA 也会使p62 水平升高,就像在DOX介导的ATG5缺失的细胞中一样 。3-MA以不同方式抑制 I 型和 III型 PI3K。与野生型细胞相比,在Tsc2−/−细胞中3-MA诱导的 LC3 I 到 LC3 II 转换过程大幅下降。3-MA会破坏mTOR复合物1的拮抗自吞噬功能[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NI\F[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOzcW0> NVzvOZhrOmh? M2PHZmROW09? NWXtRmJZemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= MYKyOVcyPjV4MR?=
A549  NFLRTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\6N41O NXLHNXJHOmh? M1zSe2ROW09? NFvqS5Bz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F MWmyOVcyPjV4MR?=
95D MUXBdI9xfG:|aYOgRZN{[Xl? M1\hfFVuVQ>? MnfvNog> NI\rVWRFVVOR M3rx[olvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= MoPSNlU4OTZ3NkG=
A549  MWnBdI9xfG:|aYOgRZN{[Xl? M1TCTlVuVQ>? MlGwNog> NVnYfGNjTE2VTx?= NVLNbW5rcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo M3;Nc|I2PzF4NU[x
NBL-W-S  M1\KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxcW0> M37CXFZp MoPn[Y5p[W6lZYOgS2FPXC14MTD0c5hq[2m2eR?= NWDOSZdWOjV|MkOyNlI>
NBL-W-S  NFnJS|NCeG:ydH;zbZMhSXO|YYm= M3TUeFFuVQ>? NIGyZos3cA>? NU\tV5RwcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhT0GQVD22NS=> M1\ubFI2OzJ|MkKy
A2780cp  MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzLNY1O NFm1RlkycA>? M2r6bYlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MXKyOVMzOjZ7NB?=
A549  MVHGeY5kfGmxbjDBd5NigQ>? MYK1cW0> NF;jUHUzcA>? NYTIfY8{e3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK MX:yOVI5PTZ{OB?=
H157 MkXXSpVv[3Srb36gRZN{[Xl? NEXCO4g2dU1? MkK3Nog> MVnzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= MUSyOVI5PTZ{OB?=
MDR NGW2PYFCeG:ydH;zbZMhSXO|YYm= M4\HclExdU1? NUjH[FFwPmh? NELLWWt{fHKnbnf0bIVveyC2aHWgdI94\XJib3[gZY51cWOjbnPldkBlenWpcx?= NYTXeWpQOjVyMUm3NFE>
HT-29  NUjiU3FISXCxcITvd4l{KEG|c3H5 MVSxcW0> MlLFOFhp MnW1SG1UVw>? MmLO[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NIfUT4ozPDh2MkG1PC=>
Microglia  MVPBdI9xfG:|aYOgRZN{[Xl? NFjYPW82dU1? M{Tye|I1cA>? NIO2OXdl\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg> M2S1[lI1QDF6NkCx
A2780cp NFT0T3ZCeG:ydH;zbZMhSXO|YYm= MmLQNk42dU1? MXuxbC=> NY\5Sop3\GSKMl:= MmXo[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NHewdlIzPDhzN{m0Oi=>
HepG2 NGTPNpFHfW6ldHnvckBCe3OjeR?= Ml24OY1O M{PxclRp MnXjbY5kemWjc3XzJGhNKHKnbHXhd4U> NVPSfHdsOjR5MUO1PFc>
A549 NGqzXWtCeG:ydH;zbZMhSXO|YYm= M3XxR|VuVQ>? MV[0PIg> NGnzbVJl\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubDDk[YF1cCCjbnSg[ZhxemW|c3nvckBt\X[nbIOgc4Yh[2G|cHHz[U0{NCCEZXPsbY4uOSCjbnSgUGM{NUmL M2Ta[VI1PzB4M{Cz
U2OS M2\SRWFxd3C2b4Ppd{BCe3OjeR?= NFTkN5QyOG2P MkDyNlRp NGHoPI1qdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? NEHZeHozPDZ|OUCxNy=>
Saos-2 M4nDZWFxd3C2b4Ppd{BCe3OjeR?= Mn7JNVBuVQ>? MWSyOIg> NVz4V49tcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 NWjxfFUxOjR4M{mwNVM>
A549 M13BR2Fxd3C2b4Ppd{BCe3OjeR?= MVKxNI1O M4Dsb|Q5cA>? MoK3ZYNk\WyncnH0[ZMhfGinIILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JHBVYA>? M{PYfVI1PjJ4N{Ky
HCT116  MYrBdI9xfG:|aYOgRZN{[Xl? M2K3ZlVuVQ>? MV2yOIg> NYjjTo9Q\W6qYX7j[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JIFxcWenbnnu MWGyOFYzPjV{Mh?=
HGC-27 NV;nbmpCTnWwY4Tpc44hSXO|YYm= MlHiNVBuVQ>? MonsNYg> MVLpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgcI9{eyCkeTDSRWQxODFib4KgUWsuOjJyNh?= M4LTblI1PDF4M{S5
U2OS  NHrIe4VHfW6ldHnvckBCe3OjeR?= MmrBNE42NzGvTR?= M2Sy[FQ5cA>? M1;veolv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NYXzbFM5OjR|NUizOFI>
MG-63 NHzBU2RHfW6ldHnvckBCe3OjeR?= MYiwMlUwOW2P M1nWeVQ5cA>? MmWwbY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> MY[yOFM2QDN2Mh?=
MG-63 MYPBdI9xfG:|aYOgRZN{[Xl? M376ZlAvPS9zbV2= MYKzNog> NX6zPIhG\W6qYX7j[ZMhe2GuaX7vcZlkcW5vaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> MYqyOFM2QDN2Mh?=
MG-63 NEPIbFRCeG:ydH;zbZMhSXO|YYm= NHL3OGYyOG2P NXzDdoFuOTKq M4L6RoVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ M4HOZlI1OzV6M{Cx
NTUB1 NGDiPIVCeG:ydH;zbZMhSXO|YYm= MUW1cW0> MYqxMlVp MlXsdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NUnmUmZ2OjR|NEmxO|Y>
T24 MWXBdI9xfG:|aYOgRZN{[Xl? NVTp[I96PW2P MlrTNU42cA>? M2qxXJBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? NIfXSFUzPDN2OUG3Oi=>
SGC-7901  MoXlRZBweHSxc3nzJGF{e2G7 NVPLOnk{Om2P M2LQfVFp NFT0bHhqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= NYjRSY5jOjR|MkGzOFA>
SMMC-7721 NYXZcndFSXCxcITvd4l{KEG|c3H5 M4L2[VJuVQ>? NFmwWJoycA>? Mk\BbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? MWSyOFMzOTN2MB?=
ECSCs  MYrBdI9xfG:|aYOgRZN{[Xl? NV3o[HZtOTCvTR?= NF3ZN|g1cA>? NWHRc5Zk\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? M{LpWVI1OzF7MUC5
MCF-7  M2TzbWZ2dmO2aX;uJGF{e2G7 NV3hcnhEOTCvTR?= NEX6V5IzPGh? MVXpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JIRzfWe| NFjpS5MzPDNzNUW3PC=>
UOK257 MWrBdI9xfG:|aYOgRZN{[Xl? NFPyXW42dU1? MlG2N4g> Mn\w[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? MmLwNlQ{ODV4MES=
ACHN-5968 NYDEWGIySXCxcITvd4l{KEG|c3H5 M4e1O|VuVQ>? MmnRN4g> MnTt[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? NWHGcnJWOjR|MEW2NFQ>
Huh7 M2T2NmFxd3C2b4Ppd{BCe3OjeR?= NYfJbo1[Om2P MWCxNog> NV24[lRQTE2VTx?= MVnpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= NXzSU25rOjR{OUezNFA>
Hep3B MWnBdI9xfG:|aYOgRZN{[Xl? M3jTTVJuVQ>? MUWxNog> NEHl[4dFVVOR NGruTGRqdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MoXyNlQzQTd|MEC=
RKO M1v3OWZ2dmO2aX;uJGF{e2G7 MnfyNo1O MlLMNYg> NIPvVmFFVVOR MWrlcohidmOnczDj[YxtKGSnYYToJIJ6KGenbHThcoFugWOrbh?= M3LaTVI1OjlzN{e3
HepG2 E47 NV6yT5lMTnWwY4Tpc44hSXO|YYm= NWrF[5QzOi53bV2= NGi4[GY1QGh? MnXubY5kemWjc3XzJJRp\SC2b4jpZ4l1gSCxZjDBRUwhSlORLDDhcoQhS0OuNB?= NV3CTJk3OjR{N{O3N|g>
LoVo  MXzBdI9xfG:|aYOgRZN{[Xl? MWW1cW0> NX7NbmJtPDiq MUPlcohidmOnczDER2EucW6mdXPl[EBieG:ydH;zbZMv MlzYNlQzODF6MUK=
WiDr MUTGeY5kfGmxbjDBd5NigQ>? NGLHO2syOG2P MkDrNYg> MmjhbY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v MVmyOFE6ODR6OR?=
H1299  NVfxU5VwTnWwY4Tpc44hSXO|YYm= NXW5b4xuOTCvTR?= M1\xeFRp MlP3bY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> Mm\xNlQyPzN{MEi=
H460 MmHsSpVv[3Srb36gRZN{[Xl? MYOxNI1O MWG0bC=> Mmn6bY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> M3jrblI1OTd|MkC4
A549 Mki4SpVv[3Srb36gRZN{[Xl? MVSxNI1O M1;xOFRp NXLnNItjcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36= NEnkTpUzPDF2MkezOS=>
Hep3B NXm2NIkySXCxcITvd4l{KEG|c3H5 MXe1cW0> MYqyOIg> M3jXVYF1fGWwdXH0[ZMhXE6ILd8xJJBzd3SnY4Tpc44h[WejaX7zeEB{\XK3bTDzeIFzfmG2aX;uMY1m\GmjdHXkJIFxd3C2b4Ppdy=> MkjVNlQxPjZ4OUO=
SMMC-7721 NIq4NZFCeG:ydH;zbZMhSXO|YYm= M{GzblVuVQ>? M2TENFI1cA>? NGL3R2lifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> M1fTSVI1ODZ4Nkmz
HO8910 M4j4e2Fxd3C2b4Ppd{BCe3OjeR?= MlmwNVBuVQ>? NX7UXpZuOTKq NXrLU3h5\W6qYX7j[ZMhSjF7LXnu[JVk\WRiYYDvdJRwe2l? NGnIPY0zOzl6M{[xNC=>
MCF7 MVXGeY5kfGmxbjDBd5NigQ>? NV7lTHZyPW2P MV[yOIg> MnX6bY5kemWjc3XzJGN2VyCrbnT1Z4VlKGOnbHyg[IVifGh? M1zqd|I{QTZ{NkK5
HONE-1  NXvlSm9DTnWwY4Tpc44hSXO|YYm= MnnKOY1O MkLiNYg> MmfwdoVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u M4nybVI{QDl{M{W4
HeLa MoDhSpVv[3Srb36gRZN{[Xl? MYmxNI1O M{DtXlJp M2\oXpN2eHC{ZYPz[ZMhVEN|IFnJJIV5eHKnc4Ppd49v NVTBXYpMOjN6NkS3N|g>
HepG2 M1nJdmZ2dmO2aX;uJGF{e2G7 MonJNVBuVQ>? M3qwU|I1cA>? MYnpcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?= Moq0NlM5OTdyNEC=
SH-SY5Y M1S3T2Z2dmO2aX;uJGF{e2G7 M4fBUFFuVQ>? M3LFVlI1cA>? NUO3R|JScW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRQS1B? Mk\iNlM4PDNzNEi=
SH-SY5Y NUK0OXFHSXCxcITvd4l{KEG|c3H5 NWjNboZGPW2P NUPze3N5OWh? NGXMRppi[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S= NFjw[GwzOzZzOUO5OS=>
PC12  MnOwSpVv[3Srb36gRZN{[Xl? MV:xNI1O M4SzO|I1cA>? NEjvOIJ4[XSnch?= Mk\WxsBqdmirYnn0d{BkcHmvb4TyfZB{cW5vbHnr[UBxem:2ZXHzc41idCCjY4Tpeol1gS5? M4HCUFI{PjB|OUe5
OV2008 MVTBdI9xfG:|aYOgRZN{[Xl? MnXpOY1O MYKyOIg> NFPuTVBkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= MnzENlM2QTJ{OEG=
A2780 NVK2OJNmSXCxcITvd4l{KEG|c3H5 Ml21OY1O NG\Odo4zPGh? M1;nS4Nwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| MlLkNlM2QTJ{OEG=
Saos-2  MojnRZBweHSxc3nzJGF{e2G7 NXfFdpRVOW2P NUL0epdqQT[q NGjQdoJqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IGDDXC=> MV[yN|U3OzF5MR?=
1321N1 MWTDfZRwfG:6aXPpeJkhSXO|YYm= M3PTXVVuVQ>? NWD1fpFEOjSq MWDwdo91\WO2czDj[YxtKGGpYXnud5QhWEOQLXnu[JVk\WRidH;4bYNqfHl? Ml;QNlM2OjV{NkW=
SH-SY5Y NVja[ZpOS3m2b4TvfIlkcXS7IFHzd4F6 M4XIdlVuVQ>? NXzaPYp2OjSq NXfZRXdbcW6lcnXhd4V{KFCFTjD0c5hq[2m2eR?= M{HUfVI{PTJ3Mk[1
HT-29  MorCSpVv[3Srb36gRZN{[Xl? M{T5dlFuVQ>? M4rP[|Q5Nzl4aB?= M3rMfolvcGmkaYTzJGFOWEtiaX7keYNmeyCjdYTvdIhi\2mlIHPlcIwh\GWjdHi= NGjhd28zOzVyOEK3Ni=>
OR6 M4\OZ2Z2dmO2aX;uJGF{e2G7 M1fvVlExdU1? NIi2WJg4Omh? NFPqNmx{fXCycnXzd4V{KEiFVjDy[ZBtcWOjdHnvckBidmRiZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| MY[yN|M6PTh5NR?=
Hela  NXfNSJBYTnWwY4Tpc44hSXO|YYm= M{X4elVuVQ>? MXuyOIg> M{LoeYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NFWwNmgzOzN7NU[3PS=>
MCF-7  NWPMTFRHTnWwY4Tpc44hSXO|YYm= Ml\qOY1O NGD5WnkzPGh? NID2NHlqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 Mn71NlM{QTV4N{m=
HUVECs MX3GeY5kfGmxbjDBd5NigQ>? MUOzcW0> NFPCSGUzPGh? MlLLZoxw[2u|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>? NH3rWpMzOzN3OEmyPC=>
T24 NF30cHlHfW6ldHnvckBCe3OjeR?= M{\lOFExdU1? M4DIV|Fp MV;y[YR2[2W|IITo[UBkdGWjdnHn[UBw\iCOQ{OgZYZ1\XJiYnHpZ4FtcW5idILlZZRu\W62 NIjMbXIzOzN3NEC4NC=>
U251MG  NFzEWlNHfW6ldHnvckBCe3OjeR?= MWGzcW0> MnzCNYg> NVrmbVhue3WycILld5NmeyCOQ{OtTWkheHKxdHXpckBmgHC{ZYPzbY9v M1zkXFI{OzN6NkG4
GTL-16  MmLiRZBweHSxc3nzJGF{e2G7 NH21Xno2dU1? Ml:0NlRp MUHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGG|IHPvcZBiemWmIITvJINmdGy|IITy[YF1\WRid3n0bEBOTVRiaX7obYJqfG:{cx?= NYe1O2xHOjN|MUO0PVA>
T-47D MWDGeY5kfGmxbjDBd5NigQ>? NYDhN2RvOTCvTR?= NXPIUJB3Omh? NYruN4JwcW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= NX;OO2JFOjN|MECwNlY>
PaCa44 NF\lXoNCeG:ydH;zbZMhSXO|YYm= MVWyMlVuVQ>? M3jiTFFp MoWydoVlfWOnc9Mg[4VvcXCrbj3t[YRq[XSnZDDhdI9xfG:|aYO= M4jId|I{OTJ2MUGy
MDA-MB231 MWHGeY5kfGmxbjDBd5NigQ>? NFLnRWM2dU1? MkXNNYg> MWTpcoNz\WG|ZYOgdoV{fmW{YYTyc4wudWWmaXH0[YQh[2G|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYTo NXvweGpyOjNyOEi4OVA>
HeLa MmnnRZBweHSxc3nzJGF{e2G7 MkXDNVBuVQ>? MmfoNog> NY\TUWNY\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0cYVvfCC5aYToJHBGUQ>? NYfCfHdkOjNyMECxN|U>
SK-HEP-1 M1L2cWFxd3C2b4Ppd{BCe3OjeR?= M{TQPVExdU1? M1m3TVFp MVvwdo91\WO2czDh[4FqdnO2IHH1eI9xcGGpeTDhcoQhcW6mdXPld{BieG:ydH;zbZMhcW5iYoXmZYxqdi22cnXheIVlKGOnbHzz NHW5TnAzOjh3OE[0PS=>
HepG2 NITnXIJCeG:ydH;zbZMhSXO|YYm= NV21UVBsO22P MX[1bC=> NGjGZmpz\WS3Y3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgVWR{ MVyyNlg{PjV7NR?=
MCF-7  MUPGeY5kfGmxbjDBd5NigQ>? M{TwNFJuVQ>? M{TIdlI1cA>? NWTFd|k5cW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> MnXxNlQ6PzB4N{[=
MDA-MB-231 NF7CXodHfW6ldHnvckBCe3OjeR?= MoXGNo1O MUCyOIg> NX3MdJE4cW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> M4DVVFI1QTdyNke2
MCF-7  MnTOSpVv[3Srb36gRZN{[Xl? MVGycW0> MYi0PIg> NWXrdHdNeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MmfZNlQ6PzB4N{[=
MDA-MB-231 NVTzN5B5TnWwY4Tpc44hSXO|YYm= M3vROFJuVQ>? MlnUOFhp NWjaZlNFeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MnfMNlQ6PzB4N{[=
PANC-1  M{jWZ2Fxd3C2b4Ppd{BCe3OjeR?= NITxSmwydU1? NWjvUXdjPDiq Mn3PSG1UVw>? NYq2eHZr\W6qYX7j[ZMh[m:{dHX6c41q[i2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? NXf2cWNMOjR6NEKxOVg>
MDA-MB 231 M1ftTGFxd3C2b4Ppd{BCe3OjeR?= NULXPHVbPW2P MkCyNE42cA>? NFzmNG1ud2S3bHH0[ZMhXG:lb33pcuKvyqCrbnT1Z4VlKGGyb4D0c5Nqew>? Mom3NlQ5OzB5OEG=
Microglia  M{G4dWFxd3C2b4Ppd{BCe3OjeR?= NGjJOmo2dU1? M1vDflI1cA>? MV;k[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NX7oUmVKOjR6MUi2NFE>
A2780cp MX;BdI9xfG:|aYOgRZN{[Xl? M2OxRVIvPW2P NUDK[5p{OWh? NF3rb2Vl\Eh{Tx?= M3\MZ4VvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NXP5RllGOjR6MUe5OFY>
HepG2 NIfIPYNHfW6ldHnvckBCe3OjeR?= NI\vO|M2dU1? NX[xNHVOPGh? NXjWWZFDcW6lcnXhd4V{KGOnbHz1cIFzKGyndnXsd{Bw\iCKTNMg MXWyOFcyOzV6Nx?=
U2OS NW\iWVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xNI1O MVWyOIg> MXvpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g> MWOyOFY{QTBzMx?=
HCT116 NXS3Uog1SXCxcITvd4l{KEG|c3H5 NIG0XFI2dU1? MkPENlRp Mn:1SG1UVw>? Mlvn[Y5p[W6lZYOgZZBq\2WwaX6tbY5lfWOnZDDj[YxtKGSnYYTo MWqyOFYzPjV{Mh?=
MCF-7  MVPBdI9xfG:|aYOgRZN{[Xl? NEX0UGgxNjGvTR?= M1Hi[|Zp MUjlcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?= NVnOb|NLOjJ5NUG5PFk>
PC-3  MV3BdI9xfG:|aYOgRZN{[Xl? NF34VlgzdU1? NF:3NGczcA>? MojFbY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? NYXEcWVHOjJ5NEW1PFA>
U251  MYXBdI9xfG:|aYOgRZN{[Xl? MlfWOY1O NFzFbYkzPGh? NVz2bGJRcW6lcnXhd4V{KFNzLXnu[JVk\WRiY3XscEBl\WG2aB?= MmrLNlI2Pzl5OEi=
HeLa  M2nuWWFxd3C2b4Ppd{BCe3OjeR?= NXjibpF7PW2P M2P1W|I1cA>? M{jtNolv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZ4VtdCCmZXH0bC=> NF3B[4YzOjV2NUGyPC=>
A549 MlfFSpVv[3Srb36gRZN{[Xl? NHnwSocxNjGvTR?= NHLmUGgzPGh? NF7rRoh{fXCycnXzd4V{KFOXMUGyO|QucW6mdXPl[EBk\WyuIHTlZZRp Mn;DNlI1PjZ7NkC=
pDCs M4r1b2Z2dmO2aX;uJGF{e2G7 NID0dWMyOG2P MlHsNE42cA>? Mn3PxsBz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gTWZPNc7zIHL5JJN{Wk6DNEC= MUKyNlM6PjV7OR?=
BGC-823 NUX2OFJqTnWwY4Tpc44hSXO|YYm= MUG1cW0> NVXUXFZSOmh? NYO3O2JFcW6qaXLpeJMhfGinIILheIUhd2ZiYYX0c5Bp[WerYzDj[Yxtew>? NEfVfoUzOjN{MkG1Ni=>
U937 M1\he2Z2dmO2aX;uJGF{e2G7 NVS0dnNPOm2P NUn2PXVuOTKq NUG0cpps\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= NIXS[WMzOjF3NUG1NC=>
Marc-145 M3PkTmZ2dmO2aX;uJGF{e2G7 NFHmZXg2dU1? MXqxNk8zPC9|Nni= M4LwdpJm\HWlZYOgeIhmKFCUUmPWJJRqfGW{czDhcoQhfGinIIDyc5RmcW5iZYjwdoV{e2mxbh?= NUjE[nl5OjJzMUm5NFA>
HBx  M4jMXmFxd3C2b4Ppd{BCe3OjeR?= MUGxNI1O M3HmOVQ5cA>? M4rUZWROW09? M{\DeIlv[3KnYYPld{Bk\WyuIHTlZZRp MYiyNlAzODB5OB?=
MCF-7 MWjGeY5kfGmxbjDBd5NigQ>? MmPUNVBuVQ>? MYW0PIg> MoD2Zoxw[2u|IHH1eI9xcGGpeTDpcoR2[2WmIHL5JIJwenSnen;tbYI> M3S5TlIyQTNzOUO3
RMPI8226  M2S5[2Z2dmO2aX;uJGF{e2G7 MW[1cW0> NX\2ZW17OWh? M1HtPJN2eHC{ZYPz[ZMhfGinIHzleoVtKG:oIHH1eI9xcGGpeTD1coRmeiCwdYTybYVvfCCmZYDs[ZRqd25? MmfINlE6OTV4MkC=
PC12/TetOn MVHGeY5kfGmxbjDBd5NigQ>? NGjQblYxNjFxMX3N NH3zeYoyQGh? NHLle3lt\WGmczD0c{DPuS2|eX6oW3QqKGGlY4XteYxifGmxbjygeI95cWOrdImsJIFv\CCxbHnnc41meiCob4LtZZRqd28EoB?= NIS0fWczOTlyNk[1PS=>
HeLa  NGWxPVZEgXSxdH;4bYNqfHliQYPzZZk> NYPqRYxrOm2P M4DQR|I1cA>? NIjSUnhqdmirYnn0[ZMhfGinIHP5eI91d3irY3n0fUBw\iC|aXzpZolvcW5idH:gTIVN[SClZXzsd{4> NHXMTVIzOTh5NUO4OS=>
Jurkat M33CfmZ2dmO2aX;uJGF{e2G7 NYnkOYQ6OTCvTR?= M4jG[VFp MmH0[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MV[yNVg3PDB|Nx?=
K562 MlzOSpVv[3Srb36gRZN{[Xl? Mkf0NVBuVQ>? NYnhSWlLOWh? NGmzbm9l\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MlrDNlE5PjRyM{e=
Nara-H NGDZWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L5NlVuVQ>? NIXrSY01QGh? NF7tR4lmdmijbnPld{B1\W2|aYLvcIlufXOvZXTpZZRm\CC|dYDwdoV{e2mxbjDv[kBP[XKjLVigZ4VtdCCycn;sbYZmemG2aX;u NY\heJhTOjF6MEWwN|M>
HUVECs MVzGeY5kfGmxbjDBd5NigQ>? Mm\iNVBuVQ>? NHy3WJcxNjWq M33DTYRm[3KnYYPld{B1cGViQVfFMWJUSWmwZIXj[YQh[XW2b4DoZYd6KGyndnW= NXXmdnBoOjF2Nki1PVI>
HepG2 MXLBdI9xfG:|aYOgRZN{[Xl? MkT4No1O MmG0NYg> NX3WSYtI\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDDk[YF1cA>? NHvifokzOTR3M{[5NS=>

... Click to View More Cell Line Experimental Data

体内研究 3-Methyladenine (3-MA)可以通过对磷酸肌醇3磷酸激酶(PI3K) 的作用来阻断自吞噬, 而PI3K的活性对于自噬体形成早期膜池的成核和组装是必须的。与SAH 处理组相比3-MA并不会改变出血的程度。与SAH +对照成分组相比经过3-MA预处理后会明显加重神经病学症状。3-MA处理会减少自吞噬发生[5]。 相反地,在SAH + 3-MA组里 断裂的半胱天冬酶表达量明显上调,与此一致的是与SAH + 对照成分组相比,SAH + 3-MA组中右脑皮层里原位末端标记阳性细胞数量明显增多[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[4]
+ 展开

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
细胞实验:[2]
+ 展开
  • Cell lines: HeLa 细胞系
  • Concentrations: 1-10 mM
  • Incubation Time: 3 分钟
  • Method: 用台盼蓝染色法分析细胞存活率(如HeLa细胞)。简言之, 经过3-MA处理后将贴壁的与漂浮的细胞都用PBS( pH 7.4)重悬,密度控制在每毫升1-2×106。加入等体积的0.4% 台盼蓝并彻底混匀。室温孵育3分钟后用血细胞计数器对细胞计数分析。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 体重 300-350 g 的成年雄性Sprague–Dawley 大鼠
  • Formulation: 生理盐水配制
  • Dosages: 400 nM
  • Administration: 脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 149.15
化学式

C6H7N5

CAS号 5142-23-4
稳定性 powder
别名 NSC 66389

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • 回答:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)供应商 | 采购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)价格 | 3-Methyladenine (3-MA)生产 | 订购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID